IA
SNDX icon

IFP Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

IFP Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Sell
669
-122
-15% -$2.54K ﹤0.01% 3165
2026
Q1 		$18.5K Hold
791
– – ﹤0.01% 2821
2025
Q4 		$16.6K Buy
791
+740
+1,451% +$12.9K ﹤0.01% 2813
2025
Q3 		$785 Buy
+51
New +$668 ﹤0.01% 4031
2025
Q2 		– Hold
0
– – – 4010
2025
Q1 		– Hold
0
– – – 4026
2024
Q4 		– Hold
0
– – – 4246
2021
Q1 		– Sell
-31
Closed -$700 – 3211
2020
Q4 		$1K Buy
+31
New +$643 ﹤0.01% 2817

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

IFP Advisors's SNDX Position: Q2 2026 in Review

IFP Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 15% in Q2 2026, selling an estimated $2.54K and leaving 669 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3165.

IFP Advisors first reported a position in SNDX in Q4 2020 and has held it in 5 quarters since. The position peaked at $18.5K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • IFP Advisors held 669 shares of Syndax Pharmaceuticals worth $14.6K as of Q2 2026.
  • IFP Advisors sold 122 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.54K.
  • Syndax Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3165 holding.
  • IFP Advisors first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
  • IFP Advisors's Syndax Pharmaceuticals position peaked at $18.5K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.